Blood advances

Mast Cell Leukemia: Clinical and Molecular Features and Survival Outcomes of Patients in the ECNM Registry.

Blood advances

Kennedy VE, Perkins C, Reiter A, Jawhar M, Lübke J, Kluin-Nelemans HC, Shomali W, Langford C, Abuel J, Hermine O, Niedoszytko M, Gorska A, Mital A, Bonadonna P, Zanotti R, Tanasi I, Mattsson M, Hagglund HG, Triggiani M, Yavuz AS, Panse JP, Christen D, Heizmann M, Shoumariyeh K, Müller S, Elena C, Malcovati L, Fiorelli N, Wortmann F, Vucinic V, Brockow K, Fokoloros C, Papageorgiou SG, Breynaert C, Bullens D, Doubek M, Ilerhaus A, Angelova-Fischer I, Solomianyi O, Varkonyi J, Sabato V, Rüfer A, Schug T, Hermans MAW, Belloni Fortina A, Caroppo F, Bumbea H, Gulen T, Hartmann K, Oude Elberink H, Schwaab J, Arock M, Valent P, Sperr W, Gotlib J

Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium.

Blood advances

Stefanski H, Eaton A, Baggott C, Rossoff J, Verneris MR, Keating AK, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, Margossian SP, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Egeler E, Mavroukakis S, Curran KJ, Mackall CL, Laetsch TW, Schultz LM

Real-World Use of Tisagenlecleucel in Infant Acute Lymphoblastic Leukemia.

Blood advances

Moskop A, Pommert L, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski H, Talano JA, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Guest EM, Breese EH, Schultz LM

Molecular profile of FLT3-mutated relapsed/refractory AML patients in the phase 3 ADMIRAL study of gilteritinib.

Blood advances

Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E

Consensus statement for the perinatal management of patients with α thalassemia major.

Blood advances

MacKenzie TC, Amid A, Angastiniotis M, Butler C, Gilbert S, Gonzalez J, Keller RL, Kharbanda S, Kirby-Allen M, Koenig BA, Kyono W, Lal A, Lianoglou BR, Norton ME, Ogasawara KK, Panchalee T, Rosner M, Schwab M, Thompson A, Waye JS, Vichinsky E

Tisagenlecleucel Outcomes in Relapsed/Refractory Extramedullary ALL: A Pediatric Real World CAR Consortium Report.

Blood advances

Fabrizio VA, Phillips CL, Lane A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta HL, Rossoff J, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM

Optimal fludarabine lymphodepletion is associated with improved outcomes following CAR T-cell Therapy.

Blood advances

Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta HL, Phillips CL, Rossoff J, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ

Decreased IL-10 accelerates B-cell leukemia/lymphoma in a mouse model of pediatric lymphoid leukemia.

Blood advances

Fitch B, Zhou M, Situ J, Surianarayanan S, Reeves MQ, Hermiston ML, Wiemels JL, Kogan SC

Macrophage Activation Syndrome-Like Manifestations (MAS-L) Following BCMA-directed CAR T-cells in Multiple Myeloma.

Blood advances

Kennedy VE, Wong C, Huang CY, Kambhampati S, Wolf JL, Martin TG, Shah N, Wong SW

VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis.

Blood advances

Kennedy VE, Wong CC, Hong JM, Peng TA, Brondfield S, Reilly LM, Cornett P, Leavitt AD

Pages